View all news

Masimo Honors Birthday of Mahatma Gandhi With Global Holiday


IRVINE, Calif.--(BUSINESS WIRE)--Oct. 2, 2016-- Masimo (NASDAQ: MASI) announced today that in honor of the birthday of Mahatma Gandhi (October 2, 1869), the company will close worldwide and offer an additional paid holiday to employees on Monday, October 3rd.

Mahatma Gandhi, born Mohandas Karamchand Gandhi, is considered the preeminent leader of the Indian independence movement, famous for seeking change, conflict resolution, and agreement through nonviolent protest, often through public fasting. He is still honored today as a global symbol of peace, with his birthday a national holiday in India and celebrated worldwide as the International Day of Nonviolence.

“Masimo has chosen to honor Gandhi’s birthday to remind its employees and partners worldwide of the enduring importance of those role models who have helped shape our world for the better. At Masimo, we strive each day to remain true to our promises and responsibilities,” said Joe Kiani, Founder and CEO of Masimo. “For us, that includes being thoughtful citizens of the world, striving to improve patient care through our innovative products and technologies. In these difficult times, when injustice, violence, and hatred are never far from the headlines, it’s especially important to remember and admire the life of one who so consistently embodied peace, forgiveness, and understanding. Gandhi got what his people wanted and gained his country’s independence from British rule through peaceful civil disobedience. I hope all Masimo employees worldwide will use this extra day to take stock of their lives, their goals, and their responsibilities, and to take steps to create a more just and peaceful world.”

@MasimoInnovates | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Source: Masimo

Media Contact:
Evan Lamb, 949-396-3376

Multimedia Files:

Categories: Press Releases
View all news